EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #72352_C
芳烃受体（AHR）拮抗剂
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
StemRegenin1 (SR1) 是芳烃受体 (AHR) 的拮抗剂。它能够促进 CD34+ 人造血干细胞体外扩增，并促进非人灵长类动物诱导多能干细胞生成 CD34+ 造血祖细胞。SR1 已被证明可与 UM729 协同作用，在培养中阻止急性髓性白血病（AML）细胞的分化。SR1 还能刺激 CD34+ 造血祖细胞增殖并分化为树突状细胞。本产品以该分子的盐酸盐形式提供。
维持和自我更新
·促进培养的人造血干细胞的维持和扩增（Boitano et al., Csaszar et al.）。
分化
·刺激CD34+造血祖细胞分化为功能性人树突状细胞（Thordardottir et al.）。
促进诱导多能干细胞（iPS）的造血分化。（Gori et al.）。
癌症研究
·与UM729协同作用，抑制培养的 AML 细胞分化（Pabst et al.）。
别名
SR1（盐酸盐）
细胞类型
癌细胞及细胞系，树突状细胞（DCs），造血干/祖细胞，白血病/淋巴瘤细胞，多能干细胞
种属
人，小鼠，非人灵长类，其他物种，大鼠
应用
分化，扩增
研究领域
癌症，干细胞生物学
CAS 编号
2319882-01-2
化学式
C₂₄H₂₃N₅OS · HCl
分子量
466.0 g/mol
纯度
≥98%
通路
AHR
靶点
AHR
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (3)
文献 (4)
Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
Science (New York,N.Y.) 2010 SEP
Abstract
Although practiced clinically for more than 40 years,the use of hematopoietic stem cell (HSC) transplants remains limited by the ability to expand these cells ex vivo. An unbiased screen with primary human HSCs identified a purine derivative,StemRegenin 1 (SR1),that promotes the ex vivo expansion of CD34+ cells. Culture of HSCs with SR1 led to a 50-fold increase in cells expressing CD34 and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice. Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR). The identification of SR1 and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy.
Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling.
Cell stem cell 2012 FEB
Abstract
Clinical hematopoietic transplantation outcomes are strongly correlated with the numbers of cells infused. Anticipated novel therapeutic implementations of hematopoietic stem cells (HSCs) and their derivatives further increase interest in strategies to expand HSCs ex vivo. A fundamental limitation in all HSC-driven culture systems is the rapid generation of differentiating cells and their secreted inhibitory feedback signals. Herein we describe an integrated computational and experimental strategy that enables a tunable reduction in the global levels and impact of paracrine signaling factors in an automated closed-system process by employing a controlled fed-batch media dilution approach. Application of this system to human cord blood cells yielded a rapid (12-day) 11-fold increase of HSCs with self-renewing,multilineage repopulating ability. These results highlight the marked improvements that control of feedback signaling can offer primary stem cell culture and demonstrate a clinically relevant rapid and relatively low culture volume strategy for ex vivo HSC expansion.
Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells.
Blood 2012 SEP
Abstract
Induced pluripotent stem cell (iPSC) therapeutics are a promising treatment for genetic and infectious diseases. To assess engraftment,risk of neoplastic formation,and therapeutic benefit in an autologous setting,testing iPSC therapeutics in an appropriate model,such as the pigtail macaque (Macaca nemestrina; Mn),is crucial. Here,we developed a chemically defined,scalable,and reproducible specification protocol with bone morphogenetic protein 4,prostaglandin-E2 (PGE2),and StemRegenin 1 (SR1) for hematopoietic differentiation of Mn iPSCs. Sequential coculture with bone morphogenetic protein 4,PGE2,and SR1 led to robust Mn iPSC hematopoietic progenitor cell formation. The combination of PGE2 and SR1 increased CD34(+)CD38(-)Thy1(+)CD45RA(-)CD49f(+) cell yield by 6-fold. CD34(+)CD38(-)Thy1(+)CD45RA(-)CD49f(+) cells isolated on the basis of CD34 expression and cultured in SR1 expanded 3-fold and maintained this long-term repopulating HSC phenotype. Purified CD34(high) cells exhibited 4-fold greater hematopoietic colony-forming potential compared with unsorted hematopoietic progenitors and had bilineage differentiation potential. On the basis of these studies,we calculated the cell yields that must be achieved at each stage to meet a threshold CD34(+) cell dose that is required for engraftment in the pigtail macaque. Our protocol will support scale-up and testing of iPSC-derived CD34(high) cell therapies in a clinically relevant nonhuman primate model.
更多信息
| Molecular Weight | 466.0 g/mol |
|---|---|
| 物种 | 人, 其它物种, 大鼠, 小鼠, 非人灵长类 |
| Alternative Names | SR1 (Hydrochloride) |
| Cas Number | 2319882-01-2 |
| Chemical Formula | C₂₄H₂₃N₅OS · HCl |
| 纯度 | ≥ 98% |
| Target | AHR |
| Pathway | AHR |
相关产品
-
StemSpan™ SFEM II用于培养和扩增造血细胞的无血清培养基
-
StemRegenin 1芳烃受体（AHR）拮抗剂
沪公网安备31010102008431号
在线联系